Lake Street analyst Brooks O’Neil raised the firm’s price target on Augmedix (AUGX) to $8 from $6 and keeps a Buy rating on the shares after introducing a forecast for 2024. Augmedix is “in a position to become one of the leaders in the burgeoning world of healthcare informatics” as a result of their unique tools and capabilities, an ongoing partnership with Google (GOOGL) and a new opportunity with HCA Healthcare (HCA), argues the analyst, who senses “this company is just scratching the surface of an immense opportunity.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUGX:
- Augmedix and Ellipsis Health partnering in automated mental health screenings
- Augmedix announces partnerships with Myndshft, Ellipsis, Sullivan Group
- Augmedix announces Augmedix Go, an AI medical documentation product
- Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician-Controlled Mobile App
- Augmedix announces inaugural AI Advisory Council members